Aligos Therapeutics
ALGS

$0.54

0.02%

Market Cap: 42.2M

About: Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Employees: 67

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

599% more call options, than puts

Call options by funds: $5.99M | Put options by funds: $0

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

50% more capital invested

Capital invested by funds: $30.1M [Q4 2023] → $45.3M (+$15.2M) [Q1 2024]

23% more funds holding

Funds holding: 40 [Q4 2023] → 49 (+9) [Q1 2024]

0.55% more ownership

Funds ownership: 63.13% [Q4 2023] → 63.67% (+0.55%) [Q1 2024]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 1 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ALGS.

See Analyst Rankings

Financial journalist opinion

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B (CHB), positive data from the Phase 1b study of ALG-000184, development plans, and the chronic suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT.

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Zacks Investment Research

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The abstracts released today can be found on the EASL website at www.easlcongress.eu.

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024.

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Zacks Investment Research

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets.

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Zacks Investment Research

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

See News Rankings